任天堂
医学
特发性肺纤维化
肺
纤维化
酪氨酸激酶抑制剂
间质性肺病
病理
内科学
癌症
作者
Kevin R. Flaherty,Athol U. Wells,Vincent Cottin,Anand Devaraj,Simon Walsh,Yoshikazu Inoue,Luca Richeldi,Martin Kolb,Kay Tetzlaff,Susanne Stowasser,Carl Coeck,Emmanuelle Clerisme-Beaty,Bernd Rosenstock,Manuel Quaresma,Thomas Haeufel,Rainer-Georg Goeldner,Rozsa Schlenker‐Herceg,Kevin K. Brown
标识
DOI：10.1056/nejmoa1908681
摘要
In patients with progressive fibrosing interstitial lung diseases, the annual rate of decline in the FVC was significantly lower among patients who received nintedanib than among those who received placebo. Diarrhea was a common adverse event. (Funded by Boehringer Ingelheim; INBUILD ClinicalTrials.gov number, NCT02999178.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
蓝天
科研狗
pluto
ll
热心市民小红花
奔跑的黑熊仔
zzc7
不懈奋进
null
蓝莓橘子酱
Mic
你嵙这个期刊没买
子车茗
charint
aaaaaa
哈47
不配.
贪玩的秋柔
地表飞猪
皖公网安备34019202002308
